Abstract | BACKGROUND: Additional topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks. OBJECTIVE: METHODS: Two identically designed, vehicle-controlled, double-blind studies enrolled and randomly assigned (2:1, crisaborole:vehicle) patients aged 2 years or older with an Investigator's Static Global Assessment (ISGA) score of mild or moderate for twice-daily application for 28 days. The primary end point was ISGA score at day 29 of clear (0)/almost clear (1) with 2-grade or greater improvement from baseline. Additional analyses included time to success in ISGA score, percentage of patients achieving clear/almost clear, reduction in severity of AD signs, and time to improvement in pruritus. RESULTS: More crisaborole- than vehicle-treated patients achieved ISGA score success (clear/almost clear with ≥2-grade improvement; AD-301: 32.8% vs 25.4%, P = .038; AD-302: 31.4% vs 18.0%, P < .001), with a greater percentage with clear/almost clear (51.7% vs 40.6%, P = .005; 48.5% vs 29.7%, P < .001). Crisaborole-treated patients achieved success in ISGA score and improvement in pruritus earlier than those treated with vehicle (both P ≤ .001). Treatment-related adverse events were infrequent and mild to moderate in severity. LIMITATIONS: Short study duration was a limitation. CONCLUSIONS:
Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD.
|
Authors | Amy S Paller, Wynnis L Tom, Mark G Lebwohl, Robin L Blumenthal, Mark Boguniewicz, Robert S Call, Lawrence F Eichenfield, Douglass W Forsha, William C Rees, Eric L Simpson, Mary C Spellman, Linda F Stein Gold, Andrea L Zaenglein, Matilda H Hughes, Lee T Zane, Adelaide A Hebert |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 75
Issue 3
Pg. 494-503.e6
(Sep 2016)
ISSN: 1097-6787 [Electronic] United States |
PMID | 27417017
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Boron Compounds
- Bridged Bicyclo Compounds, Heterocyclic
- Dermatologic Agents
- Ointments
- Cyclic Nucleotide Phosphodiesterases, Type 4
- crisaborole
|
Topics |
- Administration, Cutaneous
- Adolescent
- Adult
- Aged
- Boron Compounds
(adverse effects, therapeutic use)
- Bridged Bicyclo Compounds, Heterocyclic
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Cyclic Nucleotide Phosphodiesterases, Type 4
(adverse effects, therapeutic use)
- Dermatitis, Atopic
(complications, drug therapy)
- Dermatologic Agents
(adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Ointments
- Pruritus
(drug therapy, etiology)
- Young Adult
|